OA10158A - Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists - Google Patents

Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists Download PDF

Info

Publication number
OA10158A
OA10158A OA60663A OA60663A OA10158A OA 10158 A OA10158 A OA 10158A OA 60663 A OA60663 A OA 60663A OA 60663 A OA60663 A OA 60663A OA 10158 A OA10158 A OA 10158A
Authority
OA
OAPI
Prior art keywords
formula
methoxy
amino
cis
dihydro
Prior art date
Application number
OA60663A
Other languages
English (en)
Inventor
Van Georges Henri Paul Daele
Jean-Paul René Marie Bosmans
Van Willy Joannes Carolus Laerhoven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of OA10158A publication Critical patent/OA10158A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dental Preparations (AREA)
OA60663A 1992-11-20 1995-05-19 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists OA10158A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20

Publications (1)

Publication Number Publication Date
OA10158A true OA10158A (en) 1996-12-18

Family

ID=25526607

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60663A OA10158A (en) 1992-11-20 1995-05-19 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Country Status (31)

Country Link
US (2) US5674868A (fi)
EP (1) EP0669919B1 (fi)
JP (1) JP2830952B2 (fi)
KR (1) KR0166661B1 (fi)
AT (1) ATE176232T1 (fi)
AU (1) AU680640B2 (fi)
BG (1) BG62489B1 (fi)
BR (1) BR9307477A (fi)
CA (1) CA2149044C (fi)
CZ (1) CZ287262B6 (fi)
DE (1) DE69323322T2 (fi)
DK (1) DK0669919T3 (fi)
ES (1) ES2129615T3 (fi)
FI (1) FI952458A0 (fi)
GR (1) GR3029831T3 (fi)
HU (2) HUT72740A (fi)
IL (3) IL119273A0 (fi)
LV (1) LV10956B (fi)
MX (1) MX9307257A (fi)
NO (2) NO307690B1 (fi)
NZ (1) NZ257854A (fi)
OA (1) OA10158A (fi)
PL (1) PL176051B1 (fi)
RO (1) RO115160B1 (fi)
RU (1) RU2116072C1 (fi)
SG (1) SG47488A1 (fi)
SK (1) SK282378B6 (fi)
TW (1) TW294595B (fi)
UA (1) UA49792C2 (fi)
WO (1) WO1994012494A1 (fi)
ZA (1) ZA938676B (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
KR100529512B1 (ko) 1997-04-18 2005-11-22 얀센 파마슈티카 엔.브이. 장 세척 촉진을 위한 5ｈｔ3 길항제의 용도
HUP0003078A3 (en) * 1997-07-11 2002-02-28 Janssen Pharmaceutica Nv (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
EP1646615B1 (en) * 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
EP1687277B1 (en) 2003-11-20 2018-04-04 Janssen Pharmaceutica NV 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
CN1882549B (zh) 2003-11-20 2011-02-23 詹森药业有限公司 用作聚(adp-核糖)聚合酶抑制剂的7-苯基烷基取代的2-喹啉酮和2-喹喔啉酮
NZ551801A (en) 2004-06-30 2009-11-27 Janssen Pharmaceutica Nv Quinazolinedione derivatives as PARP inhibitors
AU2005259188B2 (en) 2004-06-30 2011-03-31 Janssen Pharmaceutica N.V. Quinazolinone derivatives as PARP inhibitors
EP1771175B1 (en) 2004-06-30 2015-12-23 Janssen Pharmaceutica NV Phthalazine derivatives as parp inhibitors
DK2134691T3 (da) 2007-03-08 2012-05-07 Janssen Pharmaceutica Nv Quinolinonderivativer som parp- og tank-inhibitorer
ES2448870T3 (es) 2007-10-26 2014-03-17 Janssen Pharmaceutica, N.V. Derivados de quinolina como inhibidores de PARP
ATE513818T1 (de) 2008-03-27 2011-07-15 Janssen Pharmaceutica Nv Chinazolinonderivate als tubulinpolymerisationshemmer
EP2271626B1 (en) 2008-03-27 2014-11-26 Janssen Pharmaceutica, N.V. Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
IL107654A0 (en) 1994-02-27
NZ257854A (en) 1997-04-24
JPH08505840A (ja) 1996-06-25
IL107654A (en) 1998-01-04
HU9501476D0 (en) 1995-07-28
DK0669919T3 (da) 1999-09-13
TW294595B (fi) 1997-01-01
HUT72740A (en) 1996-05-28
KR0166661B1 (ko) 1999-01-15
DE69323322T2 (de) 1999-09-09
BG99593A (en) 1995-12-29
BR9307477A (pt) 1999-06-29
RU2116072C1 (ru) 1998-07-27
DE69323322D1 (de) 1999-03-11
EP0669919B1 (en) 1999-01-27
CA2149044A1 (en) 1994-06-09
NO951980L (no) 1995-05-19
PL309045A1 (en) 1995-09-18
JP2830952B2 (ja) 1998-12-02
NO951980D0 (no) 1995-05-19
IL119273A0 (en) 1996-12-05
CZ287262B6 (en) 2000-10-11
US5674868A (en) 1997-10-07
ES2129615T3 (es) 1999-06-16
FI952458A (fi) 1995-05-19
CZ125895A3 (en) 1995-10-18
LV10956A (lv) 1995-12-20
ATE176232T1 (de) 1999-02-15
AU680640B2 (en) 1997-08-07
RO115160B1 (ro) 1999-11-30
GR3029831T3 (en) 1999-06-30
AU5465994A (en) 1994-06-22
US5863923A (en) 1999-01-26
NO995762D0 (no) 1999-11-24
CA2149044C (en) 2007-04-03
BG62489B1 (bg) 1999-12-30
SK282378B6 (sk) 2002-01-07
NO307690B1 (no) 2000-05-15
HU211546A9 (en) 1995-12-28
SG47488A1 (en) 1998-04-17
MX9307257A (es) 1994-05-31
PL176051B1 (pl) 1999-03-31
WO1994012494A1 (en) 1994-06-09
EP0669919A1 (en) 1995-09-06
NO995762L (no) 1995-05-19
ZA938676B (en) 1995-05-19
RU95113434A (ru) 1997-03-10
NO308530B1 (no) 2000-09-25
IL119273A (en) 2000-07-16
SK67595A3 (en) 1995-11-08
UA49792C2 (uk) 2002-10-15
FI952458A0 (fi) 1995-05-19
LV10956B (en) 1996-10-20

Similar Documents

Publication Publication Date Title
EP1499589B1 (fr) Derives de n-¬phenyl(piperidin-2-yl)methyl|benzamide, leur preparation et leur application en therapeutique
US5322844A (en) Alkoxy-4 (1H)-pyridone derivatives, processes for the preparation thereof, and pharmaceutical compositions containing them
OA10158A (en) Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists
MXPA02007318A (es) Pirrolidinas 1,3-disubstituidas como antagonistas del adrenoceptor alfa-2.
SU1313344A3 (ru) Способ получени @ -арил- @ -аминокарбоксамидов или их солей с фармацевтически приемлемой кислотой или возможной стереохимической изомерной формы
HU203724B (en) Process for producing new, substituted n-(1-alkyl-hydroxy-4-piperidinyl)-benzamide derivatives and pharmaceutical compositions containing them
US11685727B2 (en) Compounds active towards nuclear receptors
CA2344807A1 (en) Naphthalenecarboxamides as tachykinin receptor antagonists
JP3269574B2 (ja) メタノアントラセン化合物、これを含有する神経精神障害を治療するための調剤学的組成物、およびこの化合物を製造するための方法および中間体
NZ239267A (en) 3-substituted piperidine derivatives and pharmaceutical compositions
JP2014062063A (ja) スピロピペリジン誘導体
US5852016A (en) Quinoxaline derivatives useful in therapy
JP4937347B2 (ja) 置換フェニルメタノン誘導体
HU204254B (en) Process for producing pharmaceutical compositions against diarrohe containing 4-(aroyl-amino)-piperidine-butaminide derivatives and for producing the new 4-(aroyl-amino)-piperidine derivatives
EP1448566B1 (en) Chemokine receptor antagonists and methods of use thereof
JPH07179337A (ja) アルキルーフェノキシアルキルアミン誘導体を有効成分とする抗血栓剤
JPH08231504A (ja) ２−（２−インドリルエチルアミノ）−１−（３−置換フェニル）エタノール誘導体